Sponsor

Universitaetsklinikum Essen AöR

Germany Hufelandstrasse 55, Holsterhausen, 45147 Essen, Germany

About the sponsor

Clinical research in high-risk prostate cancer, very high-risk prostate cancer, and localized or locally advanced disease includes interest in PSMA PET, radioligand therapy, and preoperative treatment strategies for patients considered for radical prostatectomy or curative-intent radiotherapy.

PSMA PET imaging
Lu-PSMA radioligand therapy
Neoadjuvant prostate cancer treatment

The sponsor also studies biomarker-informed treatment selection in prostate cancer and imaging-guided approaches for defining local therapy.

About Specializations

Universitaetsklinikum Essen AöR runs clinical trials in conditions such as Non-small cell lung cancer, Prostate cancer, Colorectal cancer, Non-small cell lung cancer stage IIIB, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

10 clinical trials

Colorectal cancer+1

Recruiting

Study on Preoperative Immunotherapy with Atezolizumab and Tiragolumab for Patients with Colorectal Liver Metastases

Registered drugNo placebo

Study on Preoperative Immunotherapy with Atezolizumab and Tiragolumab for Patients with Colorectal Liver Metastases

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Universitaetsklinikum Essen AöR

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo

Study on Preoperative Treatment with Amivantamab, Carboplatin, and Pemetrexed for Patients with Resectable Non-Small-Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Universitaetsklinikum Essen AöR

Contact Research Centre

Prostate cancer

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery

Registered drugNo placebo

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Localized or Locally Advanced Prostate Cancer Eligible for Surgery

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lutetium (177LU) vipivotide tetraxetan
Sponsor:Universitaetsklinikum Essen AöR

Contact Research Centre

Prostate cancer

Not yet recruiting

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Registered drugNo placebo

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Universitaetsklinikum Essen AöR

Contact Research Centre

Gastric cancer+6

Not yet recruiting

Study on 68Ga-FAPI-46 PET Imaging for Patients with Gastrointestinal Cancers

InvestigationalNo placebo

Study on 68Ga-FAPI-46 PET Imaging for Patients with Gastrointestinal Cancers

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
Sponsor:Universitaetsklinikum Essen AöR